Research Article| Volume 312, ISSUE 1-2, P166-169, January 15, 2012

Download started.


Evaluation of apoptosis-related genes; Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients

Published:August 24, 2011DOI:


      Multiple sclerosis (MS) is a central nervous system (CNS) demyelinating disease characterized by a relapsing–remitting course leading to progressive disability. Given the critical role of apoptosis-related genes in the maintenance of homeostasis in the immune privilege sites, mutations in these genes have a profound effect on occurring autoimmune diseases such as multiple sclerosis. In the current study, polymorphisms in the apoptosis-related genes: Fas _-670 A>G, FasL _-844C>T, FasLIVS2nt _124 A>G and TRAIL_1595C>T were analyzed in 107 Iranian patients suffering from MS and 112 unrelated healthy controls using PCR-RFLP method. Our results demonstrated that among Iranian patients with MS and controls being homozygous in Fas_670A/A, G/G and FasL_-844C/C, TT in the promoter region and homozygocity in the minor allele for FasLIVS2nt_124G/G and TRAIL_1595C/C, polymorphisms were not associated with the MS risk in Iranian patients when compared with normal controls. However, the Fas _-670G/G genotype had a borderline significantly increased frequency with secondary progressive MS type (X2=5.8, P=0.05). In conclusion, no statistical association was found between the Fas, FasL and TRAIL polymorphisms and the risk of MS in Iranian patients.


      TRAIL (TNF Related Apoptosis Inducing Ligand), PCR (Polymerase Chain Reaction), RFLP (Restriction Fragment Length Polymorphism)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Macchi B.
        • Matteucci C.
        • Nocentini U.
        • Caltagirone C.
        • Mastino A.
        Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis.
        Neuroreport. 1999; 10: 399-402
        • Pender M.P.
        Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis.
        Lancet. 1998; 351: 978-981
        • Segal B.M.
        • Cross A.H.
        Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination.
        Neurology. 2000; 55: 906-907
        • Zang Y.C.
        • Kozovska M.M.
        • Hong J.
        • Li S.
        • Mann S.
        • Killian J.M.
        • et al.
        Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis.
        Eur J Immunol. 1999; 29: 1692-1700
        • Suda T.
        • Takahashi T.
        • Golstein P.
        • Nagata S.
        Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.
        Cell. 1993; 75: 1169-1178
        • Wajant H.
        The Fas signaling pathway: more than a paradigm.
        Science. 2002; 296: 1635-1636
        • Sibley K.
        • Rollinson S.
        • Allan J.M.
        • Smith A.G.
        • Law G.R.
        • Roddam P.L.
        • et al.
        Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.
        Cancer Res. 2003; 63: 4327-4330
        • Wu J.
        • Metz C.
        • Xu X.
        • Abe R.
        • Gibson A.W.
        • Edberg J.C.
        • et al.
        A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients.
        J Immunol. 2003; 170: 132-138
        • Wang Q.
        • Ji Y.
        • Wang X.
        • Evers B.M.
        Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene.
        Biochem Biophys Res Commun. 2000; 276: 466-471
        • Gray H.L.
        • Sorensen E.L.
        • Hunt J.S.
        • Ober C.
        Three polymorphisms in the 3′ UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene.
        Genes Immun. 2001; 2: 469-470
        • Zipp F.
        • Krammer P.H.
        • Weller M.
        Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.
        Immunol Today. 1999; 20: 550-554
        • Jeremias I.
        • Herr I.
        • Boehler T.
        • Debatin K.M.
        TRAIL/Apo-2-ligand-induced apoptosis in human T cells.
        Eur J Immunol. 1998; 28: 143-152
        • Mariani S.M.
        • Krammer P.H.
        Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells.
        Eur J Immunol. 1998; 28: 1492-1498
        • Gomes A.C.
        • Jonsson G.
        • Mjornheim S.
        • Olsson T.
        • Hillert J.
        • Grandien A.
        Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing–remitting multiple sclerosis.
        J Neuroimmunol. 2003; 135: 126-134
        • Poser C.M.
        • Paty D.W.
        • Scheinberg L.
        • McDonald W.I.
        • Davis F.A.
        • Ebers G.C.
        • et al.
        New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
        Ann Neurol. 1983; 13: 227-231
        • McDonald W.I.
        • Compston A.
        • Edan G.
        • Goodkin D.
        • Hartung H.P.
        • Lublin F.D.
        • et al.
        Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
        Ann Neurol. 2001; 50: 121-127
        • Bolstad A.I.
        • Wargelius A.
        • Nakken B.
        • Haga H.J.
        • Jonsson R.
        Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome.
        J Rheumatol. 2000; 27: 2397-2405
        • Bel Hadj Jrad B.
        • Mahfouth W.
        • Bouaouina N.
        • Gabbouj S.
        • Ahmed S.B.
        • Ltaief M.
        • et al.
        A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction.
        Cancer Lett. 2006; 233: 21-27
        • Stuck B.J.
        • Pani M.A.
        • Besrour F.
        • Segni M.
        • Krause M.
        • Usadel K.H.
        • et al.
        Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease.
        Hum Immunol. 2003; 64: 285-289
        • Kikuchi S.
        • Miyagishi R.
        • Fukazawa T.
        • Yabe I.
        • Miyazaki Y.
        • Sasaki H.
        TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis.
        J Neuroimmunol. 2005; 167: 170-174
        • Dowling P.
        • Shang G.
        • Raval S.
        • Menonna J.
        • Cook S.
        • Husar W.
        Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain.
        J Exp Med. 1996; 184: 1513-1518
        • Jaleco S.
        • Swainson L.
        • Dardalhon V.
        • Burjanadze M.
        • Kinet S.
        • Taylor N.
        Homeostasis of naive and memory CD4+ T cells: IL-2 and IL-7 differentially regulate the balance between proliferation and Fas-mediated apoptosis.
        J Immunol. 2003; 171: 61-68
        • Madakamutil L.T.
        • Maricic I.
        • Sercarz E.
        • Kumar V.
        Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes.
        J Immunol. 2003; 170: 2985-2992
        • Guillen C.
        • Prieto A.
        • Alvarez-Cermeno J.C.
        • de la Piedra M.
        • Gimeno A.
        • Alvarez-Mon M.
        Regulatory effects of cytokines and cyclosporine A on peripheral blood mononuclear cells from stable multiple sclerosis patients.
        Immunopharmacol Immunotoxicol. 1999; 21: 527-549
        • Huang Q.R.
        • Morris D.
        • Manolios N.
        Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene.
        Mol Immunol. 1997; 34: 577-582
        • Huang W.X.
        • Huang M.P.
        • Gomes M.A.
        • Hillert J.
        Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS.
        Neurology. 2000; 55: 928-934